As Hsp90 inhibitors target client proteins of resistant pathways, we hypothesised that C‐terminal Hsp90 inhibitors will target BRAF/MEK inhibitor resistant melanoma cells by overcoming the resistant pathways. This evidence concerns the gene BRAF and melanoma.